Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Revenue of $3.14M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Join SI Premium – FREE
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.
Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mirum Pharmaceuticals (MIRM) PT Raised to $202 at H.C. Wainwright
- MACOM Technology Solutions (MTSI) Tops Q4 EPS by 9c ; Offers Guidance
- Parker-Hannifin (PH) Tops Q1 EPS by 69c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
